Is Five Years Long Enough?

EP: 1.No Successor to OCM Would Disappoint

EP: 2.CMMI Open to Feedback, but EOM Out of the Blue

EP: 3.Some Practices That Did Not Do OCM Are Applying

EP: 4.Seven Tumor Types: Pros and Cons

EP: 5.A Model That Is Built to “Win”

EP: 6.Addressing Health Equity and Social Needs

Now Viewing

EP: 7.Is Five Years Long Enough?

EP: 8.Changes to MEOS and Barriers to Entry

EP: 9.Small Practices and Dual Risk: Considerations and Approaches

EP: 10.Does Pooling Make Sense?

EP: 11.What Would You Change About the EOM?

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates and the outgoing president of Community Oncology Alliance, sees 5 years of the EOM as a prelude to a more permanent reimbursement structure for addressing patients' social needs. Stephen Schleicher, MD, MBA, chief medical officer of Tennessee Oncology, hopes the EOM tracks progress in the ASCO Oncology Medical Home. Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, would like to see more key performance indicators added to the EOM.